AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

wherein,

(currently amended) A pharmaceutical, cosmetic,
 dietetic or nutraceutical composition comprising:

a combination of vasoactive agents consisting of a first vasoactive agent, a second vasoactive agent, and a third vasoactive agent,

 $\underline{\text{the first vasoactive agent being 0.05-2\% by weight of}}$ the composition,

 $\underline{\text{the second vasoactive agent being 0.1-1% by weight of}}$ the composition, and

the third vasoactive agent being 0.5-2% by weight of the composition,

- the first vasoactive agent is visnadin or esculoside,
- the second vasoactive agent is Ginkgo biloba dimeric
 flavones, either in a free form or complexed with phospholipids,
 or amentoflavone, and
- the third vasoactive agent is a compound selected from the group consisting of escin, escin beta-sitosterol complexed with phospholipids, and Centella asiatica extract in a free form or complexed with phospholipids.

2-3. (canceled)

4. (previously presented) The composition as claimed in claim 1, wherein the combination of vasoactive agents is incorporated into a composition is in a form selected from the group consisting of a cream, a gel, a lotion, and a milk.

5. (canceled)

6. (withdrawn-previously presented) The composition as claimed in claim 1, wherein,

the first vasoactive agent is Visnadin,

the second vasoactive agent consists of amentoflavone, and

the third vasoactive agent is escin.

7. (withdrawn-previously presented) The composition as claimed in claim 1, wherein,

the first vasoactive agent is esculoside,

the second vasoactive agent consists of amentoflavone,

the third vasoactive agent is escin.

8. (withdrawn) The composition as claimed in claim 1, wherein, $\ensuremath{\text{^{\circ}}}$

the first vasoactive agent is Visnadin, and the second vasoactive agent consists of *Ginkgo biloba* dimers in a free form or complexed with phospholipids.

9. (previously presented) The composition as claimed in claim 1, wherein,

the first vasoactive agent is Visnadin,

the second vasoactive agent is *Ginkgo biloba* dimers complexed with phospholipids, and

the third vasoactive agent is escin beta-sitosterol complexed with phospholipids.

10. (withdrawn) The composition as claimed in claim 1, wherein, $\ensuremath{\text{}}$

the first vasoactive agent is esculoside,

the second vasoactive agent is *Ginkgo biloba*dimers complexed with phospholipids, and

the third vasoactive agent is escin beta-sitosterol

complexed with phospholipids.

11-12. (canceled)

13. (previously presented) A pharmaceutical, cosmetic, dietetic or nutraceutical composition comprising:

a combination of vasoactive agents consisting of a first vasoactive agent, a second vasoactive agent, and a third vasoactive agent, wherein,

- the first vasoactive agent is visnadin,
- the second vasoactive agent is Ginkgo biloba dimeric
 flavones, either in a free form or complexed with phospholipids,
 or amentoflavone, and
- the third vasoactive agent is a compound selected from the group consisting of escin, escin beta-sitosterol complexed with phospholipids, and Centella asiatica extract in a free form or complexed with phospholipids.
- 14. (previously presented) A pharmaceutical, cosmetic, dietetic or nutraceutical composition consisting of:

a combination of vasoactive agents incorporated into a form selected from the group consisting of a cream, a gel, a lotion, and a milk; and

the combination of vasoactive agents consisting of a first vasoactive agent, a second vasoactive agent, and a third vasoactive agent, wherein,

- the first vasoactive agent is visnadin or esculoside,

- the second vasoactive agent is Ginkgo biloba dimeric
 flavones either in a free form or complexed with phospholipids,
 or amentoflavone, and
- the third vasoactive agent is a compound selected from the group consisting of escin, escin beta-sitosterol complexed with phospholipids, and Centella asiatica extract in a free form or complexed with phospholipids.